Arrivent Biopharma, Common Stock Market Value
| AVBP Stock | 29.11 0.37 1.29% |
| Symbol | ArriVent |
ArriVent BioPharma, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ArriVent BioPharma,. If investors know ArriVent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ArriVent BioPharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of ArriVent BioPharma, is measured differently than its book value, which is the value of ArriVent that is recorded on the company's balance sheet. Investors also form their own opinion of ArriVent BioPharma,'s value that differs from its market value or its book value, called intrinsic value, which is ArriVent BioPharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ArriVent BioPharma,'s market value can be influenced by many factors that don't directly affect ArriVent BioPharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ArriVent BioPharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if ArriVent BioPharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ArriVent BioPharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ArriVent BioPharma, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ArriVent BioPharma,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ArriVent BioPharma,.
| 10/29/2024 |
| 11/28/2024 |
If you would invest 0.00 in ArriVent BioPharma, on October 29, 2024 and sell it all today you would earn a total of 0.00 from holding ArriVent BioPharma, Common or generate 0.0% return on investment in ArriVent BioPharma, over 30 days. ArriVent BioPharma, is related to or competes with Magnite, Sphere Entertainment, WiMi Hologram, Grupo Televisa, Reservoir Media, BCE, and Digi International. ArriVent BioPharma, is entity of United States More
ArriVent BioPharma, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ArriVent BioPharma,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ArriVent BioPharma, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.08 | |||
| Information Ratio | 0.0043 | |||
| Maximum Drawdown | 21.03 | |||
| Value At Risk | (6.77) | |||
| Potential Upside | 5.3 |
ArriVent BioPharma, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ArriVent BioPharma,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ArriVent BioPharma,'s standard deviation. In reality, there are many statistical measures that can use ArriVent BioPharma, historical prices to predict the future ArriVent BioPharma,'s volatility.| Risk Adjusted Performance | 0.0374 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.42) | |||
| Sortino Ratio | 0.0039 | |||
| Treynor Ratio | 0.0995 |
ArriVent BioPharma, Backtested Returns
ArriVent BioPharma, appears to be not too volatile, given 3 months investment horizon. ArriVent BioPharma, secures Sharpe Ratio (or Efficiency) of 0.0545, which signifies that the company had a 0.0545% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for ArriVent BioPharma, Common, which you can use to evaluate the volatility of the firm. Please makes use of ArriVent BioPharma,'s Mean Deviation of 2.72, downside deviation of 4.08, and Risk Adjusted Performance of 0.0374 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, ArriVent BioPharma, holds a performance score of 4. The firm shows a Beta (market volatility) of 1.32, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ArriVent BioPharma, will likely underperform. Please check ArriVent BioPharma,'s expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether ArriVent BioPharma,'s price patterns will revert.
Auto-correlation | -0.16 |
Insignificant reverse predictability
ArriVent BioPharma, Common has insignificant reverse predictability. Overlapping area represents the amount of predictability between ArriVent BioPharma, time series from 29th of October 2024 to 13th of November 2024 and 13th of November 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ArriVent BioPharma, price movement. The serial correlation of -0.16 indicates that over 16.0% of current ArriVent BioPharma, price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | 0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 1.87 |
ArriVent BioPharma, lagged returns against current returns
Autocorrelation, which is ArriVent BioPharma, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting ArriVent BioPharma,'s stock expected returns. We can calculate the autocorrelation of ArriVent BioPharma, returns to help us make a trade decision. For example, suppose you find that ArriVent BioPharma, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
ArriVent BioPharma, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If ArriVent BioPharma, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if ArriVent BioPharma, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in ArriVent BioPharma, stock over time.
Current vs Lagged Prices |
| Timeline |
ArriVent BioPharma, Lagged Returns
When evaluating ArriVent BioPharma,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of ArriVent BioPharma, stock have on its future price. ArriVent BioPharma, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, ArriVent BioPharma, autocorrelation shows the relationship between ArriVent BioPharma, stock current value and its past values and can show if there is a momentum factor associated with investing in ArriVent BioPharma, Common.
Regressed Prices |
| Timeline |
Pair Trading with ArriVent BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.58 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.53 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.46 | PEPG | PepGen | PairCorr |
| 0.44 | RGNX | Regenxbio | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.